Filing summary
Important identification discrepancy: The request identifies Tuhura Biosciences, Inc. and “2014 Q3,” but the supplied filing is DelMar Pharmaceuticals, Inc.’s Form 10-Q for the quarter ended March 31, 2015, covering the three and nine months ended that date. The summary below reflects the filing text.
Business context and reporting period
DelMar is a clinical-stage cancer drug developer with no product revenue. Its lead candidate, VAL-083, is being studied for refractory glioblastoma (GBM); the company also holds certain commercial rights in China, where VAL-083 is approved for lung cancer and chronic myelogenous leukemia. The interim statements are unaudited and presented in U.S. dollars. The company changed its fiscal year-end to June 30.
Financial performance and liquidity
| Metric | Three months ended March 31, 2015 | Nine months ended March 31, 2015 | Comparable 2014 period |
|---|---|---|---|
| Revenue | No product revenue reported | No product revenue reported | No product revenue reported |
| Research and development | $641,839 | $1,925,635 | $618,869 and $1,745,164, respectively |
| General and administrative | $500,753 | $1,601,982 | $966,923 and $2,344,473, respectively |
| Net loss (income) | $1,649,136 loss | $4,048,256 loss | $3,198,607 loss and $2,729,649 income, respectively |
| Basic loss (income) per share | $0.04 loss | $0.11 loss | $0.10 loss and $0.09 income, respectively |
| Cash used in operating activities | Not separately stated | $3,044,475 | $3,030,692 |
At March 31, 2015, cash and cash equivalents were $3,006,598, working capital was $2,883,603, and total assets were $3,413,281. Cash declined by $1,753,113 from June 30, 2014. Financing activities provided $1,291,362 net during the nine-month period, principally from warrant exercises. The filing reports no conventional loan payable at period-end; a $278,530 loan from Valent had been exchanged for preferred shares. Current liabilities were $529,678; total liabilities, including warrant derivative and stock-option liabilities, were $2,196,260. The filing reports no margins because it had no product revenue.
Material changes versus comparable periods
- Quarterly net loss narrowed to $1.65 million from $3.20 million, mainly because the prior-year quarter had a larger noncash loss from remeasurement of warrant-related derivative liabilities. R&D rose 4%, while G&A fell 48%.
- For nine months, the company reported a $4.05 million loss versus $2.73 million income in 2014. The prior-year income included a $6.87 million noncash gain from derivative-liability remeasurement; the current period included a $276,963 loss from that remeasurement and $249,062 of warrant-exchange losses.
- Nine-month operating cash use was broadly unchanged year over year. R&D spending increased 10%, reflecting clinical development, drug manufacturing, regulatory, and patent activity; lower G&A largely reflected reduced share-based compensation and professional fees.
- Common shares reported on the balance sheet increased to 39,455,931 from 35,992,343 at June 30, 2014, reflecting warrant exercises and exchanges, among other issuances.
Outlook, commentary, and risks
- Management stated that warrant-exercise proceeds and available resources were expected to fund current operations through at least the end of March 2016. It also said the planned registration-directed GBM trial would require additional funding. Management was pursuing equity financing and/or strategic partnerships, with no assurance of success.
- The filing identifies a material going-concern uncertainty: the company had accumulated losses of $22,715,848, negative operating cash flow, no near-term prospect of revenue, and a need for additional capital. Failure to obtain funding could delay, reduce, or end clinical programs.
- In the ongoing Phase I/II GBM trial, the company reported dose-limiting or near-dose-limiting thrombocytopenia at 50 mg/m² and said it would not escalate beyond that dose. Dose selection and trial expansion depended on completing safety follow-up and reviewing the data. Management anticipated starting a registration-directed Phase II/III study in the second half of calendar 2015, subject to results, FDA discussions, and funding.
- The company planned to seek FDA guidance on the proposed registration trial and anticipated expanding enrollment by up to 14 additional GBM patients at a dose at or below the maximum tolerated dose. Trial results and timelines were uncertain; clinical observations were interim and from an open-label, single-arm study.
- Management planned a China post-market lung-cancer study with Guangxi Wuzhou Pharmaceuticals, targeting initiation by mid-2015. Under the collaboration, Guangxi Wuzhou was responsible for costs of China clinical trials. The company also cited supplier-certification and production-timing risks, and comparatively weak intellectual-property protection in China.
- Warrant derivative values rely on Level 3 valuation inputs and can cause significant noncash volatility in reported earnings. VAL-083’s known dose-limiting toxicity is myelosuppression. The drug was not approved outside China at the time of the filing.
Key facts for investors to verify
- Confirm the issuer and period: the supplied filing is for DelMar Pharmaceuticals, Inc., quarter ended March 31, 2015—not Tuhura Biosciences or 2014 Q3.
- Check subsequent financing after March 31, 2015, including the May 2015 financing referenced in the filing, and reassess cash runway and dilution.
- Verify the completed 50 mg/m² cohort safety data, selected expansion dose, FDA feedback, and whether the anticipated Phase II/III and China studies began as planned.
- Reconcile share-count disclosures: the filing reports 39,455,931 shares at March 31, while also stating 35,199,889 shares issued and outstanding as of May 14, 2015; it notes exchangeable shares are included on an as-exchanged basis.
- Assess the assumptions and sensitivity behind the $1,487,137 warrant derivative liability and the remaining warrant overhang.